Arterius

Executive Summary

Arterius is a UK-based medical device innovator developing advanced polymer technologies for vascular intervention. Its core platforms include a proprietary polymer coating for efficient drug delivery from balloons and the ArterioSorb™ bioresorbable scaffold (stent), both designed to leave no permanent implant in the body. The company's initial focus is on treating peripheral arterial disease (PAD), a large and growing market with significant unmet need for therapies that minimize long-term complications. By combining drug delivery with a fully bioresorbable scaffold, Arterius aims to improve patient outcomes while reducing the risks associated with permanent metal stents. Founded in 2015 and based in Leeds, the company is privately held and has not disclosed funding amounts. Its technology has the potential to disrupt the vascular intervention space, but it remains at an early stage with no publicly reported clinical data or regulatory approvals. The key challenges ahead include demonstrating safety and efficacy in clinical trials, securing regulatory clearance, and establishing manufacturing and commercial partnerships.

Upcoming Catalysts (preview)

• TBDInitiation of first-in-human clinical trial for ArterioSorb60% success
• Q4 2026Completion of preclinical studies for drug-coated balloon platform70% success
• Q1 2027CE Mark submission for ArterioSorb scaffold40% success